IL-7: Phase II started

Cytheris began the 2-year, open-label, international Phase II INSPIRE 3 trial to compare 20 µg/kg/week CYT107 vs. highly active anti-retroviral therapy (HAART) in 80 chronically HIV-1 infected patient...